Lipoprotein(a) awareness and knowledge: Lp(a)AK survey
Participation is entirely anonymous, and your input is invaluable to our mission
As part of ISCP initiatives, we are pleased to invite you to participate in the Lipoprotein(a) awareness and knowledge: Lp(a)AK survey. This anonymous survey aims to gather valuable insights into healthcare professionals' understanding of lipoprotein(a) [Lp(a)], an intriguing yet underexplored cardiovascular risk factor.
What is the survey about?
Discovered in 1963, lipoprotein(a) remains enigmatic in terms of its physiological role, though its pathophysiological impact as a cardiovascular risk factor is increasingly recognized. This survey explores:
• The level of awareness among healthcare professionals about Lp(a)
• Perceived knowledge gaps and educational needs
Who should participate?
We encourage all healthcare professionals involved in cardiovascular care—including physicians, cardiologists, general practitioners, lipid specialists, pharmacists, specialised nurses, and other related health care professionals - to take part. We endeavour to gather perspectives from as many countries as possible. To achieve this, we encourage our Members to share this survey with colleagues and professionals who are well-positioned to contribute. Your insights will help us identify global trends and knowledge gaps, shaping future ISCP educational and research efforts.
Why is your input important?
Your feedback will contribute to a better understanding of the current state of Lp(a) awareness and inform strategies to address this important yet often overlooked topic in cardiovascular health.
Next Steps?
Please complete the survey as soon as possible. Participation is entirely anonymous, and your input is invaluable to our mission.
A-Z of CV Pharmacotherapy:
ISCP Webinar Series
The latest additions to our A to Z of CV Pharmacotherapy programme are now available to view in the Webinars On Demand section:
1- Statin’ the source of that pain: Pharmacogenomics As A Preemptive Tool
2- Digitalising Care for Hypertension: One for All, All for One
3- Decongesting the current diuretic landscape in Heart Failure
4-Treating Cardiometabolic Syndromes – What’s The Best Approach?
Details of future webinars will become available in Upcoming webinars very soon, including the next series of our own A to Z of CV Pharmacotherapy programme
Have you watched one or more of the above sessions? We value your opinion. Take 3 minutes to give us feedback on the series.
Upcoming Events
13
Jan
CARE-AF/VTE International Programme
Endorsed Meeting, Webinar 13 Jan 2025
22
Jan
29
Aug
ESC 2025 MADRID
Conferences 29 Aug 2025
25
Sep
ISCP 2025 SPAIN
Annual Meeting, Conferences 25 Sep 2025
Highlights
The latest reviews, resources and expert analysis from our website.
newsfeed
Bystander CPR up to 10 minutes after cardiac arrest still can save a life
Posted on December 05, 2024
CHICAGO — Adults who received bystander CPR within the first few minutes of an out-of-hospital cardiac arrest were much more likely to... more
Severe maternal morbidity at first birth lowers likelihood of next pregnancy
Posted on December 05, 2024
Women with severe maternal morbidity after first childbirth have a lower likelihood of pursuing subsequent births, highlighting the need for reproductive counseling... more
Irregular sleep patterns may increase risk for heart attack, stroke
Posted on December 04, 2024
Irregular sleep cycles corresponded with increased risk for major adverse cardiovascular events like stroke or myocardial infarction, results from a population-based cohort... more
Aspirin not linked to nonfatal atherosclerotic CVD, death in patients with CKD
Posted on December 04, 2024
Aspirin was not linked to the risk of nonfatal atherosclerotic CVD or cardiovascular death in adults with chronic kidney disease, according to... more
ISCP book series
Current Cardiovascular Therapy
Kaski, Juan Carlos.
Series Editor: Juan Carlos Kaski Cardiovascular pharmacotherapy is a fast-moving and complex discipline within cardiology in general. New studies, trials and indications are appearing on a regular basis. This series created with the support of the International Society of Cardiovascular Pharmacotherapy (ISCP) is designed to establish the baseline level of knowledge that a cardiovascular professional needs to know on a day-to-day basis. The information within is designed to allow readers to learn quickly and with certainty the mode of action,...
-
Antiplatelet and Anticoagulation Therapy
A. Ferro, D.A. Garcia (Eds.)
-
Pharmacological Treatment of Acute Coronary Syndromes
Avanzas, Pablo; Clemmensen, Peter(Eds.)
-
Atrial Fibrillation Therapy
Gheorghe-Andrei Dan, Antoni Bayes de Luna, John Camm(Eds.)
board of directors
Providing a leadership and advocacy role amongst members of their national societies.
 
-
Thomas Kahan
Past President
Affiliations/Memberships Professor of Medicine Department of Clinical Sciences, Danderyd Hospital Division of Cardiovascular Medicine (more…) more
-
Sang Hong Baek
Board Member
Sang Hong Baek is a Board Member of ISCP and also Governor for the Republic of Korea. ISCP Governors act as representatives for different countries worldwide to encourage local participation and contribute to the ISCP's educational programmes. Past president of the ISCP Professor Sang Hong Baek is Director of Heart... more
-
Pablo Avanzas
Secretary
Professor Pablo Avanzas is Director of Invasive Cardiology at Hospital Universitario Central de Asturias and Full Professor of Cardiology at University of Oviedo in Asturias, Spain. Affiliations/Memberships • Full Professor of Cardiology, University of Oviedo, Oviedo, Spain. • Director of Invasive Cardiology at Hospital Universitario Central de Asturias, Oviedo,... more
-
Alberto Lorenzatti
President
Dr. Alberto J. Lorenzatti is currently the Co-Director of the DAMIC Medical Institute / Rusculleda Foundation for Research, Teaching and Patient Care (Head of the Clinical Research network with more than 30 research sites in Argentina) and he was the Chief of Cardiology at the Cordoba Hospital, Cordoba, Argentina... more